Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism HSP90B inhibitors(Heat shock protein HSP 90-beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H43ClN2O9 |
InChIKeyCKMGYWHSTADSIG-UHFFFAOYSA-N |
CAS Registry819812-18-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plasma cell myeloma refractory | Phase 2 | US | 01 Mar 2010 | |
Plasma cell myeloma refractory | Phase 2 | PH | 01 Mar 2010 | |
Plasma cell myeloma refractory | Phase 2 | GB | 01 Mar 2010 | |
Chronic Lymphocytic Leukemia | Phase 2 | GB | 01 Apr 2007 | |
Chronic Lymphocytic Leukemia | Phase 2 | GB | 01 Apr 2007 | |
B-Cell Lymphoma | Phase 2 | - | - | |
Hematologic Neoplasms | Phase 2 | GB | - | |
Multiple Myeloma | Phase 2 | US | - | |
Multiple Myeloma | Phase 2 | GB | - | |
Multiple Myeloma | Phase 2 | PH | - |
Phase 1/2 | 95 | (tjjuqcygcr) = cxardptmmc pcpqhnfykw (plfrzvqlgi ) View more | Positive | 24 Oct 2017 | |||
Phase 1/2 | 95 | (Phase 1 & 2: KW-2478 175 mg/m^2 and Bortezomib 1.3mg/m^2) | koafvgapfl(ncwxjklbiq) = odfutdbpsw worlrxrlmo (iqhmltvgtl, itijvvfqat - jwcfkcslqz) View more | - | 05 Nov 2014 | ||
(Phase 1 Cohort 1: KW-2478 130 mg/m^2 and Bortezomib 1.0mg/m^2) | koafvgapfl(ncwxjklbiq) = gtgwuzxorw worlrxrlmo (iqhmltvgtl, tqaitupzba - qjclfbbspu) View more |